All Videos

Frits Stulp, Implement Consulting, discusses the exciting potential of AI and “trusted regulatory spaces” for drug discovery and delivery.

Mandy Vink, VP of Business Development at Codexis, explains how the company leverages over 20 years of expertise in small-molecule APIs to advance biocatalysis across pharma.

Britton Jimenez, SVP of Sales and Marketing at Codexis, explains how the ECO Synthesis® Manufacturing Platform overcomes the limitations in scalability and sustainability that currently challenge the RNA therapeutics industry.

In this episode of the Ask the Expert video series, Susan J. Schniepp, Regulatory Compliance Associates (RCA), and Siegfried Schmitt, Parexel, tackle the ever-growing problem of having a properly trained workforce with a variety of needed skill sets.

A long-term, trust-based CDMO partnership can support cell and gene therapy developers from early process development through GMP manufacturing and commercial supply.

Jonathan Haigh, Head of UK Sites, FUJIFILM Biotechnologies, explores how advanced technologies are being used to reduce risk and strengthen global supply chains for biologics.

Biopharmaceutical manufacturers can strategically choose between fed-batch and continuous manufacturing to balance scalability, flexibility, and market demand across the product lifecycle.

In Episode 30, John Androsavich, Benjamin Fryer, and John Wilkerson go behind the headlines.

Pharma R&D, formulation, and manufacturing are transforming via HPAPI advances, AI-driven automation, EU regulatory shifts, and patient-centric drug design.

In Episode 29, John Androsavich, Benjamin Fryer and John Wilkerson go behind the top headlines from 2025.

The biannual AustinPx Amorphous Solid Dispersions (ASD) Workshop is a place for collaboration and innovation. Hear firsthand from attendees about challenges and insights from the front lines of amorphous drug development.

Digital transformation, AI, 3D printing, and proactive maintenance are reshaping pharma, speeding discovery and demanding new manufacturing standards.

Biopharma quality control is being revolutionized by advanced analytics and digital transformation through a synergy that boosts quality and scalability.

AI transforms formulation, bioanalysis, and manufacturing; accelerated FDA reviews demand parallel development readiness; new nasal spray enhances patient drug access.

Watch this interview and learn how advances in patient-centric drug delivery are transforming ten23 health's development strategies as a next-generation CDMO.

AI, in-silico modeling, and rational design streamline drug formulation; rapid regulatory pathways demand pre-submission perfection in quality and parallel execution.

In this episode of the Ask the Expert video series, Susan J. Schniepp, Regulatory Compliance Associates (RCA), Siegfried Schmitt, Parexel, and Anita Michaels, RCA, explain how CDMOs can best handle regulatory inspections and client expectations.

The conclusion of this interview with Sanjay Konagurthu focuses on simulations and calculations that go beyond simple screening.

Sanjay Konagurthu of Thermo Fisher Scientific discusses how AI and ML can help solve the dilemma of poor solubility.

To meet rising demand, developers of precision radiopharmaceutical therapies must overcome challenges in global isotope supply and align R&D platforms with evolving FDA guidance on clinical dosimetry.

Mechanistic models and hypothesis-driven strategies generate optimized efficient solutions for drug development, says Catalent’s Nathan Bennette at AAPS PharmSci 360.

Accelerated drug development insights using AI/digital twins, advanced bioanalysis, targeted delivery, and optimized formulation stability models.

To prevent catastrophic loss of expertise and investment, government and academic leaders say coordinated policy and significant investment in workforce talent are urgently needed in the UK.

At AAPS PharmSci 360 2025, Elly Zhou says digital twins helped forecast the effects of drugs on human drugs via a digital control arm.

Siddhant Sojitra, Alexion, defines in an AAPS PharmSci 360 2025 presentation an agitation model to reliably test stability for early-stage biologics.

Pharmaceutical Technology® spoke with Steve Lowes, senior director of Scientific Affairs at IQVIA Laboratories, ahead of AAPS PharmSci 360 to discuss some of the unique instruments used to conduct bioanalysis.

Pharmaceutical Technology® spoke with Steve Lowes, senior director of Scientific Affairs at IQVIA Laboratories, ahead of AAPS PharmSci 360 to discuss method validation of biomarker bioanalysis.

Long Yuan, PhD, director of the Department of Drug Metabolism and Pharmacokinetics at Biogen, provides a look into some of the trends impacting bioanalysis in biopharmaceutical development and manufacturing.

AI is transforming pharma R&D, bioanalysis, and manufacturing. The industry faces intense competition (obesity wars) and FDA regulatory instability.

Pharmaceutical Technology® spoke with Steve Lowes, senior director of Scientific Affairs at IQVIA Laboratories, ahead of AAPS PharmSci 360 to discuss how LC–MS is used in bioanalysis.